by The genetic testing market was estimated at US$ 8 billion last year and is projected to hit around US$ 15.8 billion by 2030, registering a CAGR of 7.6% between 2021 and 2030. The report contains 180+ pages with detailed analysis.
The rising prevalence of chronic diseases and technological advancements resulted in the development of efficient and innovative genetic testing kits. The rising awareness regarding the benefits of genetic testing among the global population is boosting the adoption of the genetic testing. Furthermore, the growing geriatric population across the globe is expected to drive the demand for the genetic testing as old age people are prone to the chronic diseases.
According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 ad this number is expected 2.1 billion by 2050. The presence of numerous top market players and their heavy investments in the research & development activities has encouraged innovation in the product design, improved distribution, and enhanced quality of the products. The increasing popularity of the online DNA testing kit providers such as Ancestry.com and 23andme.com is fueling the sales of the genetic testing kits.
Download a Free Sample Pages (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1389
The rising popularity of the direct-to-consumer channels and increased adoption of self-testing kits is expected to drive the growth of the global genetic testing market during the forecast period. Furthermore, the increased disposable income, rising consumer expenditure on healthcare, technological advancements, growing government initiatives to spread the awareness regarding genetic testing, and easy availability of genetic testing services are the major factors that drives the growth of the genetic testing market across the globe.
Scope of the Genetic Testing Market
| Report Coverage | Details |
| Market Size in 2021 | USD 8 Billion |
| Growth Rate From 2021 to 2030 | CAGR of 7.6% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
North America dominated the market in 2020. This is due to the increased awareness regarding the benefits of genetic testing, increased consumer expenditure on healthcare, growing geriatric population, and increased prevalence of chronic diseases in the region. Furthermore, the increased popularity of self-testing kits through online websites in the nation like US has boosted the adoption of the genetic testing kits among the population.
The aggressive marketing strategies adopted by the online test kit providers is playing a crucial role in spreading the awareness. For instance, Ancestry.com invested around US$ 109.0 million on TV ads in US, in 2016. 23andme.com spent US$ 21 million on TV ads. All these factors have significantly boosted the growth of the genetic testing market in North America.
Asia Pacific is expected to register a significant growth rate during the forecast period. This is due to the rising government initiatives to spread the awareness regarding the genetic testing. The increased disposable income, increased healthcare expenditure, increasing prevalence of chronic diseases are the major factors that are expected to boost the market growth in this region.
The lack of awareness and low disposable income in the developing and underdeveloped nation is a major restraining factor that can hamper the market growth during the forecast period. Moreover, lack of proper healthcare infrastructure in the underdeveloped nations is major disadvantage faced by the genetic testing market.
The rising popularity of self-testing or do it yourself testing is the latest trend in the market. Various sellers of the genetic testing kits are offering the testing kits with home delivery option which is making the adoption of the genetic testing kits affordable and convenient.
Read Also: SCADA Market is Estimated to Reach USD 61.22 Billion by 2030
Based on the test type, the prenatal & newborn testing segment is expected to be the fastest-growing segment during the forecast period. This is attributed to the increased demand for people in the developed countries to identify any health complications in the prenatal or the new born babies. The prenatal screening helps in identification of various health conditions such as down syndrome.
Based on the disease, the cancer segment dominated the market in 2020. This is simply attributed to the rising prevalence of various cancer diseases among the population such as breast cancer, lungs cancer, bowel cancer, and womb cancer. According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe.
The global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. Hence the rising cases of cancer is expected to sustain the dominance of this segment throughout the forecast period.
In August 2020, Guardant Health acquired the approval from FDA for its Guardant 360 CDx. The various developmental strategies like acquisition, partnerships, mergers, and government policies fosters market growth and offers lucrative growth opportunities to the market players.
The key players profiled in the global genetic testing market are
- Genentech Inc.
- Sorenson Genomics, LLC
- Abbott Molecular
- Bayer Diagnostics
- Biocartis
- BioHelix
- Celera Genomics
- Genomic Health
- HTG Molecular Diagnostics
- PacBio
Market Segmentation of Genetic Testing Market
By Test Type
- Carrier Testing
- Predictive Testing
- Diagnostic Testing
- Prenatal & Newborn Testing
- Nutrigenomics
- Pharmacogenomics
- Others
By Disease
- Cancer
- Alzheimer’s
- Thalassemia
- Cystic Fibrosis
- Huntington’s Disease
- Duchenne Muscular Dystrophy
- Other Diseases
Regional Segmentation
- North America (U.S. and Canada)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Genetic Testing Market
5.1. COVID-19 Landscape: Genetic Testing Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Genetic Testing Market, By Test
8.1. Genetic Testing Market, by Test Type, 2021-2030
8.1.1. Carrier Testing
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Predictive Testing
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Diagnostic Testing
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Prenatal & Newborn Testing
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Nutrigenomics
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Pharmacogenomics
8.1.6.1. Market Revenue and Forecast (2019-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Genetic Testing Market, By Disease
9.1. Genetic Testing Market, by Disease, 2021-2030
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Alzheimer’s
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Thalassemia
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Cystic Fibrosis
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Huntington’s Disease
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Duchenne Muscular Dystrophy
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Genetic Testing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test (2019-2030)
10.1.2. Market Revenue and Forecast, by Disease (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Disease (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Disease (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test (2019-2030)
10.2.2. Market Revenue and Forecast, by Disease (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Disease (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Disease (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Disease (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Disease (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test (2019-2030)
10.3.2. Market Revenue and Forecast, by Disease (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Disease (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Disease (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Disease (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Disease (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test (2019-2030)
10.4.2. Market Revenue and Forecast, by Disease (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Disease (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Disease (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Disease (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Disease (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test (2019-2030)
10.5.2. Market Revenue and Forecast, by Disease (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Disease (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Disease (2019-2030)
Chapter 11. Company Profiles
11.1. Genentech Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Sorenson Genomics, LLC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Molecular
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer Diagnostics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Biocartis
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. BioHelix
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Celera Genomics
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Genomic Health
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. HTG Molecular Diagnostics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. PacBio
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy this Premium Research Report@https://www.precedenceresearch.com/checkout/1389
